Overexpression of CXXC5 is a strong poor prognostic factor in ER+ breast cancer

Fang,Lei; Wang,Yu; Gao,Yang; Chen,Xuejun

doi:10.3892/ol.2018.8647

Overexpression of CXXC5 is a strong poor prognostic factor in ER+ breast cancer

Authors:
- Lei Fang
- Yu Wang
- Yang Gao
- Xuejun Chen
View Affiliations

Affiliations: Department of Pathology and Pathophysiology, Jinzhou Medical University, Jinzhou, Liaoning 121000, P.R. China, Department of Radiology and NFCR Center for Molecular Imaging, Case Western Reserve University, Cleveland, OH 44106‑5065, USA, Department of Oncology, The First Affiliated Hospital of Liaoning Medical University, Jinzhou, Liaoning 121000, P.R. China
Published online on: May 7, 2018 https://doi.org/10.3892/ol.2018.8647
Pages: 395-401
Copyright: © Fang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

CXXC5 is a newly identified CXXC‑type zinc finger family protein, which is encoded by the CXXC5 gene localised to the 5q31.3 chromosomal region. Previous studies revealed that CXXC5 is associated with various malignant tumours. The aim of the present study was to investigate the prognosis prediction of CXXC5 in different breast cancer subtypes via the Gene Expression Omnibus database and bc‑GenExMiner. CXXC5 overexpression was observed as associated with a poor prognosis for oestrogen receptor positive (ER+) breast cancer. Basal‑like breast cancer and triple‑negative breast cancer also suggest a poor prognosis, however their CXXC5 expression was low and could not be used as a prognostic factor. The CXXC5 correlated genes and their enriched Gene Ontology (GO) terms were obtained. Among those enriched GO terms, GO:0070062 (extracellular exosome) had the greatest number of associated genes and the associated genes of GO:0000122 (negative regulation of transcription from RNA polymerase II promoter) and GO:0008134 (transcription factor binding) contained CXXC5. These results suggest that overexpression of CXXC5 is a strongly poor prognostic factor in ER+ breast cancer. However, the role of CXXC5 in breast cancer requires further investigation.

View Figures

View References

1	Donepudi MS, Kondapalli K, Amos SJ and Venkanteshan P: Breast cancer statistics and markers. J Cancer Res Ther. 10:506–511. 2014.PubMed/NCBI
2	DeSantis CE, Fedewa SA, Sauer Goding A, Kramer JL, Smith RA and Jemal A: Breast cancer statistics, 2015: Convergence of incidence rates between black and white women. CA Cancer J Clin. 66:31–42. 2016. View Article : Google Scholar : PubMed/NCBI
3	DeSantis CE, Siegel RL, Sauer AG, Miller KD, Fedewa SA, Alcaraz KI and Jemal A: Cancer statistics for African Americans, 2016: Progress and opportunities in reducing racial disparities. CA Cancer J Clin. 66:290–308. 2016. View Article : Google Scholar : PubMed/NCBI
4	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
5	Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015. View Article : Google Scholar : PubMed/NCBI
6	Ufen MP, Köhne CH, Wischneswky M, Wolters R, Novopashenny I, Fischer J, Constantinidou M, Possinger K and Regierer AC: Metastatic breast cancer: Are we treating the same patients as in the past? Ann Oncol. 25:95–100. 2014. View Article : Google Scholar : PubMed/NCBI
7	Zervoudis S, Iatrakis G, Tomara E, Bothou A, Papadopoulos G and Tsakiris G: Main controversies in breast cancer. World J Clin Oncol. 5:359–373. 2014. View Article : Google Scholar : PubMed/NCBI
8	Marino N, Woditschka S, Reed LT, Nakayama J, Mayer M, Wetzel M and Steeg PS: Breast cancer metastasis: Issues for the personalization of its prevention and treatment. Am J Pathol. 183:1084–1095. 2013. View Article : Google Scholar : PubMed/NCBI
9	Nalejska E, Mączyńska E and Lewandowska MA: Prognostic and predictive biomarkers: Tools in personalized oncology. Mol Diagn Ther. 18:273–284. 2014. View Article : Google Scholar : PubMed/NCBI
10	Gasparri ML, Casorelli A, Bardhi E, Besharat AR, Savone D, Ruscito I, Farooqi AA, Papadia A, Mueller MD, Ferretti E and Panici Benedetti P: Beyond circulating microRNA biomarkers: Urinary microRNAs in ovarian and breast cancer. Tumor Biol. 39:10104283176955252017. View Article : Google Scholar
11	Ye N, Wang B, Quan ZF, Cao SJ, Wen XT, Huang Y, Huang XB, Wu R, Ma XP and Yan QG: Functional roles of long non-coding RNA in human breast cancer. Asian Pac J Cancer Prev. 15:5993–5997. 2014. View Article : Google Scholar : PubMed/NCBI
12	Pendino F, Nguyen E, Jonassen I, Dysvik B, Azouz A, Lanotte M, Ségal-Bendirdjian E and Lillehaug JR: Functional involvement of RINF, retinoid-inducible nuclear factor (CXXC5), in normal and tumoral human myelopoiesis. Blood. 113:3172–3181. 2009. View Article : Google Scholar : PubMed/NCBI
13	Kühnl A, Valk PJ, Sanders MA, Ivey A, Hills RK, Mills KI, Gale RE, Kaiser MF, Dillon R, Joannides M, et al: Downregulation of the Wnt inhibitor CXXC5 predicts a better prognosis in acute myeloid leukemia. Blood. 125:2985–2994. 2015. View Article : Google Scholar : PubMed/NCBI
14	Bruserud Ø, Reikvam H, Fredly H, Skavland J, Hagen KM, van Hoang TT, Brenner AK, Kadi A, Astori A, Gjertsen BT and Pendino F: Expression of the potential therapeutic target CXXC5 in primary acute myeloid leukemia cells-high expression is associated with adverse prognosis as well as altered intracellular signaling and transcriptional regulation. Oncotarget. 6:2794–2811. 2015. View Article : Google Scholar : PubMed/NCBI
15	Yasar P, Ayaz G and Muyan M: Estradiol-estrogen receptor α mediates the expression of the CXXC5 gene through the estrogen response element-dependent signaling pathway. Sci Rep. 6:378082016. View Article : Google Scholar : PubMed/NCBI
16	Knappskog S, Myklebust LM, Busch C, Aloysius T, Varhaug JE, Lønning PE, Lillehaug JR and Pendino F: RINF (CXXC5) is overexpressed in solid tumors and is an unfavorable prognostic factor in breast cancer. Ann Oncol. 22:2208–2215. 2011. View Article : Google Scholar : PubMed/NCBI
17	Jézéquel P, Campone M, Gouraud W, Guérin-Charbonnel C, Leux C, Ricolleau G and Campion L: bc-GenExMiner: An easy-to-use online platform for gene prognostic analyses in breast cancer. Breast Cancer Res Treat. 131:765–775. 2012. View Article : Google Scholar : PubMed/NCBI
18	Tabariès S, Ouellet V, Hsu BE, Annis MG, Rose AA, Meunier L, Carmona E, Tam CE, Mes-Masson AM and Siegel PM: Granulocytic immune infiltrates are essential for the efficient formation of breast cancer liver metastases. Breast Cancer Res. 17:452015. View Article : Google Scholar : PubMed/NCBI
19	Barrett T, Wilhite SE, Ledoux P, Evangelista C, Kim IF, Tomashevsky M, Marshall KA, Phillippy KH, Sherman PM, Holko M, et al: NCBI GEO: Archive for functional genomics data sets-update. Nucleic Acids Res. 41:(Database Issue). D991–D995. 2013. View Article : Google Scholar : PubMed/NCBI
20	Badowska-Kozakiewicz AM and Budzik MP: Immunohistochemical characteristics of basal-like breast cancer. Contemp Oncol (Pozn). 20:436–443. 2016.PubMed/NCBI
21	Zhang M, Wang R, Wang Y, Diao F, Lu F, Gao D, Chen D, Zhai Z and Shu H: The CXXC finger 5 protein is required for DNA damage-induced p53 activation. Sci China C Life Sci. 52:528–538. 2009. View Article : Google Scholar : PubMed/NCBI
22	Astori A, Fredly H, Aloysius TA, Bullinger L, Mansat-De Mas V, de la Grange P, Delhommeau F, Hagen KM, Récher C, Dusanter-Fourt I, et al: CXXC5 (retinoid-inducible nuclear factor, RINF) is a potential therapeutic target in high-risk human acute myeloid leukemia. Oncotarget. 4:1438–1448. 2013. View Article : Google Scholar : PubMed/NCBI
23	Stoddart A, Qian Z, Fernald AA, Bergerson RJ, Wang J, Karrison T, Anastasi J, Bartom ET, Sarver AL, McNerney ME, et al: Retroviral insertional mutagenesis identifies the del(5q) genes, CXXC5, TIFAB and ETF1, as well as the Wnt pathway, as potential targets in del(5q) myeloid neoplasms. Haematologica. 101:e232–e236. 2016. View Article : Google Scholar : PubMed/NCBI
24	Cui Z, Shen Y, Chen KH, Mittal SK, Yang JY and Zhang G: KANK1 inhibits cell growth by inducing apoptosis though regulating CXXC5 in human malignant peripheral nerve sheath tumors. Sci Rep. 7:403252017. View Article : Google Scholar : PubMed/NCBI
25	Bettin A, Reyes I and Reyes N: Gene expression profiling of prostate cancer-associated genes identifies fibromodulin as potential novel biomarker for prostate cancer. Int J Biol Markers. 31:e153–e162. 2016. View Article : Google Scholar : PubMed/NCBI